Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C

Archives of Medical Research

Volumn 44, Issue 6, 2013, Pages 444-448

  Muñoz Espinosa, Linda E ^a   Cordero Pérez, Paula ^a   Marín López, Eduardo ^b   Torres González, Liliana ^a   Malé Velázquez, Rene ^c   Armienta Sarabia, Rolando ^d   Hernández Gómez, María Elena ^d   Núñez Camarena, José de Jesús Ernesto ^e   Olivera Martínez, Marco Antonio ^f   Sánchez Avila, Juan Francisco ^g  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b Hospital de la Beneficiencia Española   (Mexico)

^c Hospital San Javier   (Mexico)

^d CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^e Hospital la Trinidad   (Mexico)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Adverse events; Hepatitis C virus; Natural interferon alpha; Nonresponders; Sustained viral response

Indexed keywords

ALPHA INTERFERON; MULTIFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ALOPECIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; CLINICAL ARTICLE; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DYSGEUSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; MALE; MEXICO; MOUTH ULCER; MYALGIA; NAUSEA; NOSE DISEASE; OTALGIA; PARESTHESIA; PRURITUS; RASH; RETREATMENT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TYPING; VOMITING; WEAKNESS;

ADVERSE EVENTS; HEPATITIS C VIRUS; NATURAL INTERFERON ALPHA; NONRESPONDERS; SUSTAINED VIRAL RESPONSE;

ANTIVIRAL AGENTS; ASTHENIA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RETREATMENT; RIBAVIRIN; VIRAL LOAD;

EID: 84885105897     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.08.004     Document Type: Article

References (20)

1. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Bacon B.R., Shiffman M.L., Mendes F., et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after non-response to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009, 49:1838-1846.
3. Fartoux L., Degos F., Trepo C., et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007, 5:502-507.
4. DiBisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008, 359:2429-2441.
5. Jensen D.B., Freilich B., Andreone P., et al. Pegylated interferon alfa-2a (40kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kD)/RBV: final efficacy and safety outcomes of the REPEAT study [Abstract LB4]. Hepatology 2007, 46:291A-292A.
6. Kaiser S., Hass H.G., Bissinger L., et al. Comparison of daily consensus interferon versus peginterferon alfa 2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C [Abstract S1060]. Gastroenterology 2006, 130(suppl 2):A784.
7. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
8. Vierling JM. 869c: Sustained virologic response (SVR) in prior pegInterferon/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC) and PR: final results of the PROVIDE study. Presented at: Digestive Disease Week 2013; May 18-21, Orlando, FL.
9. Berg T., Hopf U., Schuff-Werner P. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-alpha in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-alpha. Am J Gastroenterol 2001, 96:612-614.
10. Musch E., Malek M., Von Eick H., et al. Successful long-term application of highly purified natural interferon-alpha (multiferon) after preceding interferon approaches in a chronic hepatitis C patient with thrombocytopenia. Scand J Infect Dis 2004, 36:395-399.
11. Musch E., Malek M., Von Eick H., et al. Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches. Hepatogastroenterology 2004, 51:1476-1479.
12. Strader D.B., Wright T., Thomas D.L., et al. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
13. Shiffman M.L., Morishima C., Dienstag J.L., et al. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology 2009, 137:1986-1994.
14. Poynard T., Schiff E., Terg R., et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previously alfa interferon/ribavirin (I/R) non-responders (NR): final results from the EPIC 3 program. J Hepatol 2008, 48:S369.
15. Jensen D.M., Marcellin P., Freilich B., et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009, 150:528-540.
16. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
17. Balagopal A., Thomas D.L., Thio C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010, 139:1865-1876.
18. Sixtos-Alonso S., Avalos-Martinez R., Dehesa-Violante M., et al. Polymorphism (SNP) RS12979860 of IL28B in Mexican patients with chronic hepatitis C and its association with virological response to PEG-IFN alpha 2b and ribavirin. J Hepatol 2011, 54:S530-S531.
19. Pacanowski M., Amur S., Zineh I. New genetic discoveries and treatment for hepatitis C. JAMA 2012, 307:1921-1922.
20. Rodriguez-Torres M., Jeffers L.J., Sheikh M.Y., et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009, 360:257-267.